Researcher Database - KOSAKA YOSHIYUKI

KOSAKA YOSHIYUKI

Department / Course

Kobe Gakuin University The Faculty of Rehabilitation Department of Occupational Therapy

Job Professor

Academic conference presentation
2016/12	Continuous cytarabine plus dexamethasone in consolidation phase to patients with childhood ALL: result from Japan Association of Childhood Leukemia Study -- JACLS ALL02 protocol. (Annual Meeting of Maerican Society of Hematology)
2016/12	Landscape of Driver Mutations and Their Clinical Impacts in Pediatric Acute Lymphoblastic Leukemia (Annual Meeting of Maerican Society of Hematology)
2016/12	Risk-adjusted therapy of acute lymphoblastic leukemia can improve survival: Results of Japan Association Childhood Leukemia Study Group (JACLS) Protocol ALL-02 (Annual Meeting of Maerican Society of Hematology)
2016/12	Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL) (Annual Meeting of Maerican Society of Hematology)
2016/12	The outcome of low-risk childhood B-cell precursor ALL treated with the Japan Association of childhood Leukemia Study (JACLS) ALL-02 trial. (Annual Meeting of Maerican Society of Hematology)
2016/04	Effects of conditioning intensity on growth after hematopoietic stem cell transplantation in children. (Annual Meeting of the European Society for Blood and Marrow Transplantation)
2015/04	Neuroblastoma minimal residual disease markers are differentially expressed in peripheral blood and bone marrow samples (Asian Society of Pediatric Research 2015)
2015/04	Two high-risk neuroblastoma cases with early detection of tumor relapse/re-growth by consecutive minimal residual disease monitoring (Asian Society of Pediatric Research 2015)
2014/12	Absolute lymphocyte counts at the end of induction is a prognostic indicator in childhood acute lymphoblastic leukemia. (Annual Meeting of American Society of Hematology)
2014/12	Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia. (Annual Meeting of Maerican Society of Hematology)
2014/12	Differentiating Burkitt Lymphoma from Burkitt-like Lymphoma in Pediatrics: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study (Annual Meeting of Maerican Society of Hematology)
2014/12	High Event-Free Survival Rate with Minimum-Dose-Anthracycline Treatment in Childhood Acute Promyelocytic Leukemia: A Nationwide Prospective Study By the Japanese Pediatric Leukemia / Lymphoma Study Group (JPLSG) (Annual Meeting of Maerican Society of Hematology)
2014/09	Aggressiveness of End of Life care for Neuroblastoma Patients (International Society of Pediatric Oncology)
2014/06	High dose topotecan, melphalan, and cyclophosphamide (TMC) with autologous peripheral blood stem cell transplant for advanced medulloblastoma, supratentorial primitive neuroectodermal tumors, and pineoblastoma (International Symposium Pediatric Oncology)
2013/12	Poor Prognosis With Different Induction Rate Was Observed In Children With Acute Myeloid Leukemia and FLT3-ITD According To The ITD/WT Allelic Ratio: A Result From The Japanese Pediatric Leukemia/Lymphoma Study Group (Annual Meeting of American Society of Hematology)
2013/12	Prognostic Significance Of CRLF2 Over-Expression In Pediatric Acute Lymphoblastic Leukemia (Annual Meeting of American Society of Hematology)
2013/12	Risk Factors for Clonal Evolution Of Acquired Bone Marrow Failure After Immunosuppressive Therapy In Children. (Annual Meeting of American Society of Hematology)
2013/09	THE Feasibility of High-dose Topotecan, Melphalan and Cyclophosphamide in Children with Advanced solid Tumors: A Single-Institution Experience. (Congrenn of International society of Pediatric Oncology)
2012/12	Appropriate Dose Modification in Induction Therapy Is Essential for the Treatment of Infants with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). (Annual Meeting of American Society of Hematology)
2012/12	Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) (Annual Meeting of American Society of Hematology)
2012/12	Excess Reduction of Anthracyclines Results in Inferior Event-Free Survival in Core Binding Factor Acute Myeloid Leukemia in Children; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) (Annual Meeting of American Society of Hematology)
2011/12	Antithymocyte Globulin (ATG), Cyclosporine (CyA), and Danazol Versus ATG and CyA As Treatment for Children with Aplastic Anemia: Result of Matched-Pair Analysis (Annual Meeting of American Society of Hematology)
2011/12	IKZF1 Deletion Is Strongly Associated with Risk of Relapse in Intermediate Risk Group in JACLS ALL02 Cohort (Annual Meeting of American Society of Hematology)
2011/12	JAK2 mutations and CRLF2 rearrangements in Down Syndrome-Associated Acute Lymphoblastic Leukemia in Japan (Annual Meeting of American Society of Hematology)
2011/12	Outcomes in Children with Severe Aplastic Anemia Receiving Bone Marrow Transplantation from an HLA-Matched Family Donor or Intensive Immunosuppressive Therapy As First-Line Treatment (Annual Meeting of American Society of Hematology)
2009/12	Mutations in Ribosomal Protein Genes of Diamond-Blackfan Anemia Patients in Japan (Annual meeting of American Society of Hematology)
2008/12	Predicting Response to Immunosuppressive Therapy in Childhood Aplastic Anemia. (Annual Meeting of American Society of Hematology)
2008/12	Relapse of Children with Aplastic Anemia after Immunosuppressive Therapy (Annual Meeting of American Society of Hematology)
2008/05	Expression of HER2/neu is Uncommon in Childhood Neuroblastomas but not in Human Neuroblastoma Cell Lines (Advances Neuroblastoma Research 2008)
2008/04	Clonal expansion of an MLL-AF3p21 fusion gene in the absence of leukaemia (Congress of the European Hematology Association)
2007/12	Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia (Annual Meeting of American Society of Hematology ()